I gave Claude access to my Home Assistant. It helped me audit, debug, and improve my smart home better than I ever could have.
Sydnexis Receives Complete Response Letter from FDA for SYD-101 to Slow Pediatric Myopia Progression
DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug ...
IISET IAT 2026 Answer Key: The Indian Institutes of Science Education and Research (IISER) has released the IISER Aptitude Test (IAT) 2026 answer key on June 7, 2026, after conducting the entrance ...
Democratic state Assemblywoman Claire Valdez – who is running to replace retiring Rep. Nydia Velázquez – accepted $7,000 in donations in January from Silicon Valley-based billionaire AI investor and ...
FDA feedback centered on CMC documentation and quality/manufacturing controls, a common first-cycle barrier that typically does not necessitate additional efficacy or safety trials. Pediatric ...
You might’ve heard that Phillies starter Cristopher Sánchez just recorded one of the best calendar months the sport has seen in a very, very long time. He has thrown 44 2/3 consecutive scoreless ...
Content from Forbes Advisor Brand Group is presented as part of a paid partnership with our advertisers. A business checking account may look simple on paper. But for a growing company, it rarely ...
In the absence of head-to-head randomized trials, ImmunityBio conducted a matching-adjusted indirect comparison (MAIC) using individual patient data from QUILT-3.032 (Cohort A, NAI+BCG, n=100) ...
Winning a national championship requires elite talent and quality depth. Only a handful of programs entering the 2026 season can check both boxes as legitimate title contenders with complete rosters.
Highlights of Python 3.15, now available in beta, include lazy imports, faster JITs, better error messages, and smarter profiling. The first full beta of Python 3.15 ...
The FDA has doled out two manufacturing-related complete response letters (CRLs), slamming the brakes on prospective therapies from AbbVie and Grace Therapeutics. For AbbVie, the Chicago drugmaker had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results